ONKOLOGIK KASALLIKLAR FONIDA VIRUSLI GEPATITLAR: ZAMONAVIY QARASHLAR

Hamida Ibraximova

Mualliflar

Hamida Ibraximova Urganch davlat tibbiyot institute yuyuqumli kasalliklar, epidemiologiya va ftiziatriya kafedrasi dotsenti, PhD, Urganch sh., O‘zbekiston ##default.groups.name.author##

Kalit so‘zlar:

Virusli gepatit, onkologik kasalliklar, HBV reaktivatsiyasi, HCV reaktivatsiyasi, immunomodulyatsiya

Abstrak

Onkologik kasalliklarga chalingan bemorlarda virusli gepatitlar (ayniqsa HBV va HCV) ning klinik kechishi va asoratlari global tibbiy ahamiyatga ega. Kimyoterapiya, radioterapiya va immunoterapiya fonida virusning latent holatdan faol replikatsiyaga o‘tishi, ya’ni reaktivatsiya xavfi sezilarli darajada ortadi. Bu jarayon klinik belgilar va laboratoriya ko‘rsatkichlarining o‘zgarishi, jigar funksiyasining susayishi, fulminant gepatit hamda terapiya rejasining o‘zgarishiga olib kelishi mumkin.

Xalqaro tadqiqotlar bilan bir qatorda, O‘zbekiston olimlari ham virusli gepatitlar tarqalishi, klinikasi va profilaktika choralari bo‘yicha keng miqyosda ilmiy ma’lumotlar taqdim etmoqda. Ushbu maqolada zamonaviy jahon adabiyoti va mahalliy tadqiqotlar asosida virusli gepatitlarning onkologik kasalliklar fonida tarqalishi, patogenezi, klinik xususiyatlari, diagnostika va monitoringi, profilaktika hamda davolash choralari tahlil qilindi.

Maqola nafaqat klinik shifokorlar, balki epidemiologlar, virusologlar va tibbiy tadqiqotchilar uchun ham foydali ma’lumotlarni o‘z ichiga oladi. Shuningdek, HBV va HCV reaktivatsiyasini solishtiruvchi jadvallar, xavf omillari va terapevtik yo‘llar ham taqdim etildi. Yaqin istiqbolda virusli gepatitlarni nazorat qilish va onkologik kasalliklarni davolash strategiyasini takomillashtirish uchun fundamental va amaliy bilimlar taqdim etiladi.

##plugins.themes.default.displayStats.downloads##

##plugins.themes.default.displayStats.noStats##

Havolalar

1. Schweitzer A, et al. Lancet, 2015; 386:1546–1555.

2. EASL Clinical Practice Guidelines: Management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.

3. Terrault NA, et al. Hepatology. 2018;67:1560–1599.

4. Yeo W, et al. J Clin Oncol. 2003;21:300–306.

5. Paul S, et al. Gastroenterology. 2016;150:152–164.

6. Lok AS, et al. N Engl J Med. 2012;366:1319–1327.

7. Torres HA, et al. Blood Rev. 2019;33:38–49.

8. Lok AS, McMahon BJ. Hepatology. 2009;50:661–662.

9. Hsu C, et al. J Clin Oncol. 2008;26:620–626.

10. Chen M, et al. Clin Gastroenterol Hepatol. 2010;8:123–131.

11. Yeo W, et al. Hepatology. 2000;32:635–639.

12. Loomba R, et al. Hepatology. 2008;47:119–128.

13. Paul S, et al. Gastroenterology. 2016;150:152–164.

14. Torres HA, et al. Clin Liver Dis. 2018;22:513–529.

15. HDV International Study Group. J Hepatol. 2019;70:327–335.

16. WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis B virus infection. 2015.

17. EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2020;73:1170–1218.

18. GLOBOCAN 2020: Liver Cancer Fact Sheet.

19. El-Serag HB. N Engl J Med. 2011;365:1118–1127.

20. Perz JF, et al. J Hepatol. 2006;45:529–539.

21. Yeo W, et al. Ann Oncol. 2004;15:233–239.

22. Terrault NA, et al. Hepatology. 2016;63:261–283.

24. Ismoilov U.Y., Musabaev E.I., Khikmatullaeva A.S. Hepatitis B and C prevalence study in Uzbekistan (1 048 575 screening cohort). Eur J Public Health. 2025;35:1014–1023.

25. Rustamova Sh.O., Bakiyeva M.Sh., Rakhmanov T.O. Viral hepatitis C/HIV coinfection and IL28B polymorphism in Uzbekistan. PNR J. 2024;8:12–20.

26. Oslonov A.A., Kadirov J.F. Clinical and laboratory diagnosis of viral hepatitis. Tashkent: SamMU Press, 2023.

27. Matnazarova G.S., Saidkasimova N.S., Ismailov O.D. Dynamics of viral hepatitis incidence in Uzbekistan. MJST. 2022;4:55–63.

28. Awareness and knowledge of hepatitis B and C in Uzbekistan: 2022 survey. BMC Public Health. 2023;23:459.